



Biotron *ASX:BIT*

Novel Small-Molecule Antiviral Drugs

Michelle Miller, CEO
mmiller@biotron.com.au



Biotron Ltd Overview




- Established in 1999 as a spin-out from the Australian National University, Canberra; Based in Sydney, Australia
- IPO on ASX in Jan 2001 (Ticker code BIT)
- Focus on developing novel small molecule antiviral drugs
 - Hep C, HIV, Dengue
- Key highlights
 - Successful implementation of clinical trials for the Hep C and HIV programs
 - Successful capital raisings in challenging market conditions (A\$2.7 m in 2010)
- Experienced team, including
 - Dr Michelle Miller (CEO) - Ex-J&J; Investment Manager with specialist bioscience fund manager
 - Dr Carolyn Luscombe (Development Manager) – ex-Viridae and ViroMed
 - Dr Michael Hirshorn – Ex-Cochlear & ResMed; private equity fund manager
 - Dr Denis Wade – Ex-JJR; Director of Heartware

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au



Biotron's Pipeline

- **Two** clinical phase programs:
 - Hepatitis C virus (BIT225) and HIV

Project	Target	Discovery	Preclinical	Clinical Trials		
				Phase Ia	Ph Ib	Ph IIa
Hep C	p7					
HIV	Vpu					
Dengue	M protein					

Lead Product – BIT225

- BIT225 is a new investigational oral drug in development for treating Hep C infection
- Completed two clinical trials:
 - **Phase Ia** – *Placebo-Controlled, Randomized Study of the Safety and Pharmacokinetics of BIT225 in Healthy Volunteers* (48 patient, single dose study); Status - completed
 - **Phase Ib** - *Placebo-Controlled, Randomized Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Patients (Males and Females) with Hepatitis C Virus Infection* (18 patient, multiple dose study); Status - completed in October 2009
- **Phase IIa** - *Placebo-Controlled, Randomized Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Infection*. Status - trial anticipated to complete by end 2010.

BIT225 Clinical Information

- First-in-class drug targeting p7 protein of Hep C virus
 - p7 - Critical role in production of infectious Hep C virus in infected cells
 - Proposed as new target for therapeutic intervention
- Phase Ia results indicated that BIT225 was well-tolerated at doses up to 600mg with no dose-limiting toxicities
- Phase Ib results indicated that
 - 200 mg BIT225 significantly reduced virus levels compared to placebo (p=0.0002)
 - On an individual level, 3 of the 6 subjects receiving 200 mg of BIT225 had significant reductions in viral loads.
 - Results were first indication that a p7-inhibitor has therapeutic potential
- Phase IIa – 24 subjects (Hep C+, genotype 1) commencing standard of care (SOC) will receive 200 or 400 mg BIT225 (or placebo) twice daily for first 28 days of SOC.

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au



BIT225 – Commercialization Strategy

- Hep C worldwide market ~US\$2.8 billion; predicted to expand to >US\$10 billion
- Over 170 million individuals infected causing severe liver disease, including cirrhosis and hepatocellular carcinoma
- Low response rate due to compliance issues with SOC as well as prevalence of interferon-resistant, genotype 1 virus;
- Documented need for new specific antiviral drugs for Hep C
- Potential to combine BIT225 with current approved or next generation Hep C drugs (synergistic with both *in vitro*)
- BIT225 is first-in-class
 - Biotron has back-up drugs and proprietary assays to facilitate development of 2nd generation drugs
- Strong patent protection – 5 patent families filed worldwide
- Currently unpartnered; seeking suitable partner after Phase IIa trial

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

The Biotron logo features the word "Biotron" in a bold, italicized, blue sans-serif font. The text is contained within a white rounded rectangular box with a thin blue border.

Capital Structure

Shares on issue	121.8 m
Listed options	108 m
Unlisted options	6.4 m
Cash at 30 June10	A\$1.78 m
Current market cap	A\$12.8 m

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

